touchPODCAST

touchEXPERT OPINIONS for touchIMMUNOLOGY Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis.  The expert Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchimmunologyime.org/Primary-biliary-cholangitis-therapeutic-landscape

touchEXPERT OPINIONS for touchENDOCRINOLOGY Listen to a leading expert in hepatology as they explore the current and future management of primary biliary cholangitis.  The expert Dr Mitchell Shiffman - Bon Secours Liver Institute, Richmond, VA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical educational grant from Gilead Sciences Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchendocrinologyime.org/primary-biliary-cholangitis-therapeutic-landscape

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USAInterventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USAClinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USAOncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USAMolecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchONCOLOGY.com

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USAInterventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USAClinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USAOncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USAMolecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchONCOLOGY.com

touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USAInterventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USAClinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USAOncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USAMolecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchRESPIRATORY.com

touchMDT for touchRESPIRATORY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USAInterventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USAClinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USAOncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USAMolecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchRESPIRATORY.com

touchMDT for touchRESPIRATORY What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects. The multidisciplinary team Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands Pulmonologist – Dr Lizza Hendriks,  Maastricht University Medical Center, Maastricht, The Netherlands Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

touchMDT for touchRESPIRATORY What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights. The multidisciplinary team Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

touchMDT for touchRESPIRATORY What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC. The multidisciplinary team: Pulmonologist – Dr Lizza Hendriks,  Maastricht University Medical Center, Maastricht, The Netherlands Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchrespiratoryime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

touchMDT for touchONCOLOGY What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? Listen to key experts Prof. Suresh Senan, Dr Lizza Hendriks and Dr Jacob Sands discuss the impact of ICIs on the real-world management of patients with LS-SCLC, including guidance on monitoring for and management of possible immune-related side effects. The multidisciplinary team Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands Pulmonologist – Dr Lizza Hendriks,  Maastricht University Medical Center, Maastricht, The Netherlands Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

touchMDT for touchONCOLOGY What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Jacob Sands and Prof. Suresh Senan discuss the latest data for ICIs in LS-SCLC, including data released at key congresses in 2024, and share their clinical insights. The multidisciplinary team Medical oncologist – Dr Jacob Sands Dana-Farber Cancer Institute, Boston, MA, USA Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

touchMDT for touchONCOLOGY What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC. The multidisciplinary team: Pulmonologist – Dr Lizza Hendriks,  Maastricht University Medical Center, Maastricht, The Netherlands Radiation oncologist – Prof. Suresh Senan Amsterdam University Medical Center, Amsterdam, The Netherlands This touchPODCAST is for HCPs outside the UK. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  https://touchoncologyime.org/where-to-next-in-limited-stage-small-cell-lung-cancer-the-role-of-immune-checkpoint-inhibitors/

touchEXPERT OPINIONS for touchINFECTIOUS DISEASES In this activity, Prof. Antoni Torres, a leading expert in respiratory infections, discusses the burden of pneumococcal disease in vulnerable patient populations, the evolving landscape of Streptococcus pneumoniae subtypes and the role that next-generation vaccines can play in preventing severe pneumococcal infections. The expert Prof. Antoni Torres, University of Barcelona, Spain This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.  For further information visit our website:  www.touchINFECTIOUS DISEASES.com

touchCONGRESS for touchONCOLOGY Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice. Overview Data reviews with Prof. RostiExpert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below Clinical themes Approved and emerging TKIs for CML in the first-line settingApproved and emerging TKIs for CML in the second- and later-line settingsPotential impact of emerging data on current and future clinical practiceThe internationally renowned multiple myeloma expert faculty Prof. Gianantonio Rosti: Meldola, ItalyProf. Susanne Saussele: Mannheim, Germany Dr Carla Boquimpani: Rio de Janeiro, Brazil This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan. This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.  For further information visit our website: TBC

touchCONGRESS for touchHAEMATOLOGY Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice. Overview Data reviews with Prof. RostiExpert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below Clinical themes Approved and emerging TKIs for CML in the first-line settingApproved and emerging TKIs for CML in the second- and later-line settingsPotential impact of emerging data on current and future clinical practiceThe internationally renowned multiple myeloma expert faculty Prof. Gianantonio Rosti: Meldola, ItalyProf. Susanne Saussele: Mannheim, Germany Dr Carla Boquimpani: Rio de Janeiro, Brazil This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan. This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.  For further information visit our website: TBC

touchPANEL DISCUSSION for touchNEUROLOGY Listen to a panel of leading experts discuss best practice in the management of agitation in Alzheimer’s dementia and the potential of new pharmacological approaches that target aspects of the underlying pathophysiology.  The experts Prof. Jeffrey Cummings, University of Nevada, Las Vegas, NV, USA Prof. Krista Lanctôt, University of Toronto, ON, Canada Prof. James Galvin, University of Miami, FL, USA    This touchPODCAST is for HCPs outside of the UK only.  This activity is funded by an independent medical education grant from Lundbeck. This activity is jointly provided by USF Health and touchIME in collaboration with the Gerontological Society of America (GSA). For further information visit: https://touchneurologyime.org/cme/curriculums/agitation-in-alzheimers-dementia/

touchIN CONVERSATION for touchCARDIO Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hypertension, patient risk stratification to support treatment decision-making and considerations for optimizing patient care in an evolving treatment landscape.  This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. The experts Prof. Manreet Kanwar, Allegheny General Hospital, Pittsburgh, PA, USAProf. Jean-Luc Vachiéry, Hôpital Universitaire de Bruxelles Erasme, Brussels, Belgium  For further information visit our website:  www.touchCARDIO.com

touchIN CONVERSATION for touchRESPIRATORY Listen to Prof. Manreet Kanwar in conversation with Prof. Jean-Luc Vachiéry, two experts in pulmonary arterial hypertension who are practicing in the USA and Belgium, respectively. They respond to questions submitted by the HCP audience and provide expert insights into the diagnosis of pulmonary arterial hypertension, patient risk stratification to support treatment decision-making and considerations for optimizing patient care in an evolving treatment landscape.  This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider. The experts Prof. Manreet Kanwar, Allegheny General Hospital, Pittsburgh, PA, USAProf. Jean-Luc Vachiéry, Hôpital Universitaire de Bruxelles Erasme, Brussels, Belgium  For further information visit our website:  www.touchRESPIRATORY.com

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USAInterventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USAClinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USAOncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USAMolecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchONCOLOGY.com

touchMDT for touchONCOLOGY Listen to a panel of experts discuss the use of targeted therapies for NSCLC with MET alterations. The multidisciplinary team Thoracic medical oncologist: Dr Xiuning Le, University of Texas MD Anderson Cancer Center,  Houston, TX, USAInterventional pulmonologist: Dr Christine Argento, Johns Hopkins University School of Medicine,  Baltimore, MD, USAClinical oncology pharmacist: Dr Sandra Cuellar, University of Illinois, Chicago, IL, USAOncology nurse practitioner: Ms Stephanie McDonald, Dana-Farber Cancer Institute, Boston, MA, USAMolecular pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Germany This touchPODCAST is for HCPs outside the UK. This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. For further information visit our website:  www.touchONCOLOGY.com